Last updated on February 2019

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC


Brief description of study

The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.

Clinical Study Identifier: NCT02273375

Contact Investigators or Research Sites near you

Start Over

Charles Dayen

Centre Hospitalier de Saint-Quentin
Saint-Quentin, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.